| | Conditions & Treatments | Immune System Disorders

Vaccinations and B Cell Deficiencies: Understanding Immune Response

B cell deficiencies (e.g., CVID, X-linked agammaglobulinemia, selective IgA deficiency) impair antibody production, reducing vaccine effectiveness.

Impact on Vaccine Response

Clinical Management

IVIG replacement: Provides passive antibodies; does not replace active immunity.
Vaccination strategy:
- Give inactivated/subunit vaccines (safe, may give partial/T cell benefit).
- Avoid live vaccines (unless IgG >400 mg/dL and off IVIG for months — specialist decision).
- Check post-vaccine titers (IgG specific) to document response.
- Consider higher doses, extra boosters, alternative schedules.
Household contacts: Fully vaccinated (cocooning).
Prophylactic antibiotics for encapsulated organisms (pneumococcus, H. influenzae).

Monitoring

Quantitative immunoglobulins (IgG, IgA, IgM) q3–6mo.
Vaccine-specific titers (pneumococcal, tetanus, diphtheria).
B cell enumeration (CD19+ flow cytometry).

Individualized plan with immunologist essential. Vaccines still recommended where safe—even partial protection has value.

Immune System Disorders - Related Articles

Vaccine Type	Mechanism	Effectiveness in B Cell Deficiency
Live-attenuated (MMR, varicella, rotavirus)	Replicate → robust T/B cell activation	Contraindicated (risk of vaccine-strain infection); poor antibody response anyway
Inactivated (IPV, hepatitis A, rabies)	Antigen + adjuvant → B cell dependent	Reduced/absent antibody response; may still elicit T cell immunity
Subunit/recombinant (HepB, HPV, acellular pertussis)	Protein antigen → T-dependent B cell response	Poor antibody response
Conjugate (Hib, PCV, MenACWY)	Polysaccharide-protein → converts T-independent to T-dependent	Impaired (requires functional B cells)
mRNA / Viral vector (COVID-19)	Endogenous antigen expression → strong T & B cell	Reduced antibodies; T cell response may persist
Polysaccharide (PPSV23)	T-independent → no memory	Ineffective (no class switching/memory)